Article Text

Download PDFPDF
Clinical Outcomes of Uterine Carcinosarcoma: Results of 94 Patients
  1. Zeynep Kestel Gokce, MD*,
  2. Taner Turan, MD*,
  3. Alper Karalok, MD*,
  4. Tolga Tasci, MD*,
  5. Isin Ureyen, MD*,
  6. Enis Ozkaya, MD,
  7. Mehmet Faruk Kose, MD and
  8. Gokhan Tulunay, MD*
  1. *Gynecologic Oncology Department, Etlik Zubeyde Hanim Women’s Health Teaching and Research Hospital, Kecioren, Ankara;
  2. Dr Sami Ulus Women’s Health and Children Teaching and Research Hospital, Ankara; and
  3. Department of Obstetrics and Gynaecology, Istanbul Medipol University, Istanbul, Turkey.
  1. Address correspondence and reprint requests to Tolga Tasci, MD, Gynecologic Oncology Division, Etlik Zubeyde Hanim Women’s Health Teaching and Research Hospital, Etlik St, 06010 Kecioren, Ankara, Turkey. E-mail: drtasci{at}gmail.com.

Abstract

Objective We aimed to determine the clinicopathologic features and identify prognostic factors of patients with uterine carcinosarcoma.

Materials and Methods A total of 94 patients with uterine carcinosarcoma who were diagnosed between January 1993 and October 2013 were included. Staging surgery consisted of total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, peritoneal cytology, and omentectomy. Staging is undertaken according to the 2009 International Federation of Gynecology and Obstetrics staging system. Kaplan-Meier survival analysis was used to determine the effects of variables on disease-free survival (DFS) and overall survival (OS).

Results Seventy-nine patients underwent staging surgery and none of them had residual tumor after surgery. Three-year DFS and 3-year OS were 42.7% and 59.2%, respectively. In the univariate analysis, stage, presence of para-aortic metastatic lymph nodes, uterine serosal spread, positive peritoneal cytology, and extrapelvic metastases were associated with 3-year DFS and stage, presence of para-aortic metastatic lymph nodes, uterine serosal spread, positive peritoneal cytology, adnexal involvement, and extrapelvic metastases were associated with 3-year OS. Seventy-four patients received adjuvant therapy. Adjuvant therapy did not reduce recurrence or improve survival. Any of the chemotherapy regimens was not superior to the others. In the multivariate analysis, only age was an independent prognostic factor for 3-year DFS and no parameter was statistically significant for 3-year OS.

Conclusions Age was an independent prognostic factor for 3-year DFS. Older age was associated with poor survival. Extrauterine spread was associated with survival. The aims of surgery should be both staging and providing tumoral debulking. Prospective randomized trials are needed to better define the necessity and modality of the administered adjuvant therapy.

  • Carcinosarcoma
  • Malignant mixed mullerian tumor
  • Uterine neoplasm
  • Adjuvant therapy
  • Survival

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.